Key result
GDMT plus CRT improves clinical and functional status in SLC25A20-related late-onset DCM.
Why the study?
Cardiomyopathy due to SLC25A20 mutations typically manifests neonatally with rapid progression and high mortality, but late-onset presentations are rare and not well characterized.
Case Report (n=1)
This case demonstrates that SLC25A20 mutations can cause late-onset dilated cardiomyopathy, which may respond well to standard heart failure therapies including CRT.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for GDMT plus CRT benefit in SLC25A20-related late-onset DCM; larger studies needed before changing practice.
BACKGROUND: Cardiomyopathy due to SLC25A20 mutations typically manifests in the neonatal period, characterized by rapid progression and high mortality. CASE SUMMARY: A 62-year-old man presented with late-onset dilated cardiomyopathy (DCM) associated with a heterozygous SLC25A20 c.199-10T>G mutation. Comprehensive evaluation, including biochemical testing, echocardiography, cardiac magnetic resonance imaging, and invasive coronary angiography, ruled out other potential etiologies. The patient received guideline-directed medical therapy in conjunction with cardiac resynchronization therapy, leading to significant clinical and functional improvement. DISCUSSION: To our knowledge, this represents the oldest reported case of SLC25A20-related DCM. This case highlights the clinical presentation, multimodal imaging findings, and therapeutic response in late-onset SLC25A20-related cardiomyopathy. TAKE-HOME MESSAGES: Although rare, SLC25A20 mutations can contribute to late-onset DCM. Optimized heart failure management, including multimodal therapeutic strategies, may improve cardiac function in patients with SLC25A20-related DCM.
No takes yet. Share an insight, caveat, or question.
Nguyen et al. (2025) conducted a case report in Late-onset dilated cardiomyopathy (DCM) associated with a heterozygous SLC25A20 c.199-10T>G mutation (n=1). Guideline-directed medical therapy and cardiac resynchronization therapy was evaluated on Clinical and functional improvement. Guideline-directed medical therapy combined with cardiac resynchronization therapy led to significant clinical and functional improvement in a 62-year-old man with SLC25A20-related late-onset DCM.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: